AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2017
May 13, 2017
30751_dirs_2017-05-12_4b25c1ef-82a9-4ea6-bf48-840fa143f5e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2017-05-11
Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-11 | Ordinary Shares | S | 12073 | $153.1694 | Disposed | 296418 | Direct |
| 2017-05-11 | Ordinary Shares | S | 17927 | $153.675 | Disposed | 278491 | Direct |
Footnotes
F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.5200 to $153.5150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.5200 to $154.0400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.